



# Five-Decade Update on Chemopreventive and Other Pharmacological Potential of Kurarinone: a Natural Flavanone

Shashank Kumar<sup>1\*</sup>, Kumari Sunita Prajapati<sup>1</sup>, Mohd Shuaib<sup>1</sup>, Prem Prakash Kushwaha<sup>1</sup>, Hardeep Singh Tuli<sup>2</sup> and Atul Kumar Singh<sup>1</sup>

<sup>1</sup>Molecular Signaling & Drug Discovery Laboratory, Department of Biochemistry, Central University of Punjab, Bathinda, India, <sup>2</sup>Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Ambala, India

## OPEN ACCESS

### Edited by:

Carlos Alberto Manssour Fraga,  
Federal University of Rio de Janeiro,  
Brazil

### Reviewed by:

Souvik Roy,  
NSHM Knowledge Campus, India  
Zhaofeng Liang,  
Jiangsu University, China

### \*Correspondence:

Shashank Kumar  
shashankbiochemau@gmail.com

### Specialty section:

This article was submitted to  
Pharmacology of Anti-Cancer Drugs,  
a section of the journal  
Frontiers in Pharmacology

**Received:** 06 July 2021

**Accepted:** 24 August 2021

**Published:** 27 September 2021

### Citation:

Kumar S, Prajapati KS, Shuaib M, Kushwaha PP, Tuli HS and Singh AK (2021) Five-Decade Update on Chemopreventive and Other Pharmacological Potential of Kurarinone: a Natural Flavanone. *Front. Pharmacol.* 12:737137. doi: 10.3389/fphar.2021.737137

In the present article we present an update on the role of chemoprevention and other pharmacological activities reported on kurarinone, a natural flavanone (from 1970 to 2021). To the best of our knowledge this is the first and exhaustive review of kurarinone. The literature was obtained from different search engine platforms including PubMed. Kurarinone possesses anticancer potential against cervical, lung (non-small and small), hepatic, esophageal, breast, gastric, cervical, and prostate cancer cells. *In vivo* anticancer potential of kurarinone has been extensively studied in lungs (non-small and small) using experimental xenograft models. In *in vitro* anticancer studies, kurarinone showed IC<sub>50</sub> in the range of 2–62 μM while *in vivo* efficacy was studied in the range of 20–500 mg/kg body weight of the experimental organism. The phytochemical showed higher selectivity toward cancer cells in comparison to respective normal cells. kurarinone inhibits cell cycle progression in G2/M and Sub-G1 phase in a cancer-specific context. It induces apoptosis in cancer cells by modulating molecular players involved in apoptosis/anti-apoptotic processes such as NF-κB, caspase 3/8/9/12, Bcl2, Bcl-XL, etc. The phytochemical inhibits metastasis in cancer cells by modulating the protein expression of Vimentin, N-cadherin, E-cadherin, MMP2, MMP3, and MMP9. It produces a cytostatic effect by modulating p21, p27, Cyclin D1, and Cyclin A proteins in cancer cells. Kurarinone possesses stress-mediated anticancer activity and modulates STAT3 and Akt pathways. Besides, the literature showed that kurarinone possesses anti-inflammatory, anti-drug resistance, anti-microbial (fungal, yeast, bacteria, and Coronavirus), channel and transporter modulation, neuroprotection, and estrogenic activities as well as tyrosinase/diacylglycerol acyltransferase/glucosidase/aldose reductase/human carboxylesterases 2 inhibitory potential. Kurarinone also showed therapeutic potential in the clinical study. Further, we also discussed the isolation, bioavailability, metabolism, and toxicity of Kurarinone in experimental models.

**Keywords:** kurarinone, flavanone, anticancer, apoptosis, migration, pharmacological activity

## INTRODUCTION

Plant-based secondary metabolites are indirectly helpful for the growth and development of the plants, but it is of direct importance for humans. The plant-based phytochemical/secondary metabolites can be categorized in various groups majorly based on their structural skeleton and functional groups (Kumar, 2014). Our research group reported the pharmaceutical activities of different plants and/or phytochemicals (Kumar and Pandey 2013; Mishra et al., 2013; Kumar et al., 2014; Kushwaha et al., 2019a; Kushwaha et al., 2020a; Kushwaha et al., 2020b; Kushwaha et al., 2021). Flavonoids are a group of polyphenolic compounds that occur widely in plants. They contain a benzo- $\gamma$ -pyrone structure comprised of two benzene rings (A and B), connected with a heterocyclic pyran ring (C). Flavonoids are classified as flavone, flavanol, flavanone, and others. These groups may differ from each other based on the oxidation level and type of substitution group at the C ring. They are well known for their pharmacological potential such as anticancer, antioxidant, neuroprotective, hepatoprotective, immune-modulatory, antimicrobial, antidiabetic, etc (Kushwaha et al., 2019b). Kurarinone is a natural flavanone found in different plants and possesses various pharmacological activities including chemoprevention efficacy. Literature showed anticancer, anti-fungal, anti-bacterial, anti-Corona virus, neuroprotective, anti-drug resistance, antioxidant, and anti-inflammatory potential of kurarinone. In the present review, we discuss the chemoprevention potential of kurarinone and the underlying regulatory mechanism in detail. The various pharmacological activities such as Ca<sup>+</sup> channel and glucose transporter activity modulation, metabolic enzyme, and xenobiotic metabolism enzyme inhibition potential are reviewed. The bioavailability and toxicity of a therapeutic agent are of prime concern. Thus, we also reviewed the studies based on these parameters of kurarinone.

## Kurarinone Chemistry and Natural Sources

Kurarinone is a naturally occurring prenylated flavanone. Komatsu et al. (1970) for the first time isolated kurarinone from the methanolic root extract of *Sophora angustifolia*

(Fabaceae). Briefly, the extract was chromatographed and eluted using acetone:hexane (1:1 ratio). The eluted material was subjected to thin-layer chromatography and the relatively slower-moving fraction was taken and re-chromatographed using chloroform:methanol (95:5 ratio) as elution solvent which yielded 15 g kurarinone (started with 20 kg raw plant material). Kurarinone was obtained as a colorless crystalline substance. The structure was established using UV, IR, and NMR techniques (Komatsu et al., 1970). Later, Yamahara et al. (1990) isolated the kurarinone from *Sophora flavescens* root extract, which became a choice of isolation source for the scientist in the two decades. Isolation of kurarinone from different sources and plant parts has been summarized in **Table 1**. Kurarinone contains a lavandulyl group at the C-8 position and a methoxy group at the C-5 position along with hydroxyl groups at positions C-2, C-4, and C-7. Chung et al. (2004) reported that the lavandulyl group and the positions of the hydroxyl group are important for the diacylglycerol acyltransferase inhibitory activity of kurarinone. Son et al. (2003) reported that the lavandulyl group and methoxy groups of kurarinone play important roles in tyrosinase inhibitory activity.

## Anticancer Potential


Kang et al. (2000) first reported the anticancer efficacy of *Sophora flavescens*. To isolate the compounds, the methanol extract was prepared and partitioned between dichloromethane and aqueous methanol. Further through re-chromatography kurarinone was isolated in a sub-fraction. The methanol extract of the *S. flavescens* root and isolated compounds showed potential anticancer efficacy against HL-60 cells (human myeloid leukemia). Kurarinone depicted 18.5  $\mu$ M IC<sub>50</sub> in comparison to the standard drug cisplatin (2.3  $\mu$ M IC<sub>50</sub>) (Kang et al., 2000). It has been reported that chemotherapy induces the nuclear factor NF- $\kappa$ B pathway which in turn results in the activation of survival signaling and molecular events involved in anti-apoptosis. By doing this, the NF- $\kappa$ B pathway activation plays an important role in cancer drug resistance. Bcl2, an

**TABLE 1** | Kurarinone isolation from different sources.

S. No	Source	Solvent	Part/type	Ref
1	<i>Sophora flavescens</i> Ait	Ethyl acetate extract	Root	Yamahara et al. (1990)
2	<i>Gentiana macrophylla</i>	Aqueous acetone	Root	Tan et al. (1996)
3	<i>S. flavescens</i> Ait	—	Root	Kang et al. (2000)
4	<i>S. flavescens</i> Ait	Dichloromethane fraction	—	Kim et al. (2003)
5	<i>Albizia julibrissin</i> (Leguminosae)	EtOAc fraction of the MeOH extract	—	Jung et al. (2004)
6	<i>Sophora flavescens</i>	Polyphenolic extract	Root	De Naeyer et al. (2004)
7	<i>S. flavescens</i> Ait	MeOH extracts	—	Lee et al. (2005)
8	<i>S. flavescens</i> Ait	—	—	Zhang et al. (2007)
9	<i>S. flavescens</i>	—	Root	Li et al. (2008)
10	<i>S. flavescens</i>	—	—	Ma et al. (2013)
11	<i>S. tonkinensis</i>	—	—	He et al. (2013)
12	<i>S. flavescens</i>	—	Root	Zhang et al. (2013)
13	<i>S. flavescens</i>	—	—	Zhang et al. (2016a)
14	<i>S. flavescens</i>	—	Flower	Zhang et al. (2016b)
15	Traditional Chinese Medicine Xin-Su-Ning capsule (XSNC)	—	—	Guo et al. (2018)
16	<i>S. flavescens</i>	—	—	Zhou et al. (2018)

important NF- $\kappa$ B pathway target gene, is involved in anti-apoptotic events and drug resistance in clinical oncology. Han et al. (2007) studied the efficacy of kurarinone on NF- $\kappa$ B pathway and apoptosis induction. Further, the study explored the effect of test samples on the activity of different receptor tyrosine kinases involved in clinical oncology. The *in vitro* apoptosis induction potential of the kurarinone containing extract was studied in lung and esophageal carcinoma cell lines (H460 and Eca-109, respectively). The *in vivo* apoptosis induction potential of isolated kurarinone alone and in combination with Taxol (standard anticancer drug) was studied in the lung cancer cell line xenograft model. At a dose of 100 mg/kg body weight per day, kurarinone decreased the expression of Bcl2 protein and up regulated the levels of caspase 8 and 3 in the experimental rat model. Kurarinone showed dose-dependent (5.8  $\mu$ g/ml  $IC_{50}$ ) inhibitory potential on NF- $\kappa$ B pathway activation in lipopolysaccharide induced pathway activation in an experimental model. Kurarinone inhibited induced I $\kappa$ B $\alpha$  phosphorylation (regulates NF- $\kappa$ B nuclear translocation) in HEK293 (kidney) cells at 100  $\mu$ g/ml concentration. Kurarinone inhibited EGFR and Her-2 phosphorylation (in A431 and MDA-MB-453 cell lines) at 20  $\mu$ g/ml concentration. The EGFR activity was also inhibited in *in vivo* experimental rats at 100 and 500 mg/kg body weight treatment with 14 and 40% inhibition efficacy, respectively. Moreover, kurarinone showed inhibition of KDR activity with 2.3  $\mu$ M  $IC_{50}$  (Han et al., 2007).

Sun et al. (2008) studied the anti-tumor efficacy of *S. flavescens* flavonoids in *in vitro* (A549, SPC-A-1, NCI-H460 cell lines) and *in vivo* (lung xenograft model) cancer models. The study showed that the phytochemical did not produce toxicity in the experimental rats up to 750 mg/kg bodyweight treatment. The flavonoids showed significant anti-tumor potential in lung cancer in *in vitro* and *in vivo* models at test concentrations/treatment. The study concluded that *S. flavescens* flavonoids such as kurarinone may be developed as novel anti-tumor candidates (Sun et al., 2008). Berghe et al. (2011) studied the mechanistic aspect of TNF- $\alpha$  induced NF- $\kappa$ B pathway activation in fibroblast L929sA cells. Kurarinone inhibited TNF- $\alpha$  induced IL-6 mRNA expression in transfected L929sA cells significantly at 4 and 40  $\mu$ M concentrations. Further, the TNF- $\alpha$  induced promoter activity of different genes (IL6, IL8, E-sel, PGK, and NF- $\kappa$ B) were decreased in the presence of kurarinone at 10, 25, 50, and 100  $\mu$ g/ml concentrations. Kurarinone did not affect the TNF-induced NF- $\kappa$ B binding to DNA but it significantly inhibits p42/p44 ERK phosphorylation thereby inhibiting the downstream effector molecules (p90RSK and target S6RP) at test concentrations. Further, the toxicity of kurarinone was studied in low and high metastatic *in vitro* breast cancer models (MCF7/6 and MDA-MB-231 cells, respectively). Dose-dependent activity was observed in the test cells (Berghe et al., 2011). In an interesting study, Shi et al. (2012a) studied the microbiologically transformed nor-kurarinone compounds for their anticancer potential. A total of seven compounds (kurarinone was one of them) was formed by the action of *Cunninghamella blakesleana* on the test compound and the structure was confirmed using NMR and MS techniques. Kurarinone showed toxicity against HeLa and A375 cell lines with an  $IC_{50}$  of 36 and 62  $\mu$ M, respectively (Shi




et al., 2012a) (**Figure 1**). The same research group obtained some new glycosylated compounds by transforming kurarinone in the presence of *Cunninghamella* spp. One of the transformed products named kurarinone-7-O- $\beta$ -glucoside showed 8.7  $\mu$ mol/ $IC_{50}$  against HeLa cells (Shi et al., 2012b).

Seo et al. (2012) reported the effect of kurarinone on TRAIL (TNF-related apoptosis inducing ligand) induced apoptosis and associated mechanism in HeLa cells. Results showed that kurarinone exerts apoptosis induction potential in a caspase-dependent manner at 5  $\mu$ M concentration. It showed effect neither on Bcl2 and inhibitor of apoptosis (IAP) family proteins nor on death receptors (DR4 and 5) induced cytotoxicity. TRAIL is known to induce apoptosis through TRAIL-R1/R2 (DR4/5) transmembrane receptors. Further results showed that kurarinone has the ability to potentiate the apoptosis induction potential of TRAIL via inhibiting the NF- $\kappa$ B mediated cFLIP (FLICE-inhibitory protein long form) expression (Seo et al., 2012). TRAIL is an important anticancer agent, which induces apoptosis in different types of cancer cells. Gastric cells are known to be less sensitive to TRAIL induced apoptosis. Zhou et al. (2015) studied the effect of kurarinone and TRAIL co-treatment in gastric cells (SGC7901). Kurarinone showed significant cytotoxicity to gastric cells at 10  $\mu$ M or higher concentrations. Co-treatment with the TRAIL (50 ng/ml), kurarinone showed toxicity even at lower concentrations (5  $\mu$ M). Similarly, the co-treatment significantly increased the cleaved caspase-3 and PARP proteins in comparison to treatment alone. Further, the co-treatment arrested the gastric cells in the G2/M phase and decreased the cyclin B1 and cyclin A protein expression. Kurarinone-TRAIL treatment decreased the apoptotic regulator proteins (Mcl-1 and c-FLIP) at mRNA and protein level. The result showed that the co-treatment decreases the phosphorylation of STAT3 protein which is required for the expression of Mcl-1 and c-FLIP proteins (Zhou et al., 2015).

Recently, Yang et al. (2018) studied in detail the anticancer efficacy of kurarinone in non-small cell lung cancer (NSCLC) *in vitro* and *in vivo* models. The author proposed the underlying apoptosis induction mechanism of kurarinone in NSCLC cells (A549). Kurarinone showed little toxicity on normal human bronchial epithelial cells (BEAS-2B) at 5–25  $\mu$ M concentration. The phytochemical produced dose-dependent apoptosis induction potential by decreasing the Bcl2-Bax protein ratio, activating caspase 9/3, decreasing Grp78 expression, inhibiting

caspase 12/7, and suppressing the Akt activity at 5, 10, and 25  $\mu\text{M}$  concentrations. Kurarinone did not produce toxicity in experimental rats and produced anti-cancer efficacy in the A549 xenograft rat model at a dose of 20 and 40 mg/kg body weight. Kurarinone treatment significantly reduced the tumor weight and volume in comparison to the non-treated group in 27 days of treatment (Yang et al., 2018). In a different study, Chung et al. (2019) studied the anticancer effect of kurarinone in small-cell lung cancer (SCLC) cells (H1688 and H146) and deduced the underlying mechanism. Kurarinone showed 12.5 and 30.4  $\mu\text{M}$   $\text{IC}_{50}$  for H1688 and H146 cancer cell lines, respectively. Early and late apoptotic cell population was increased in kurarinone treated cells. The cleaved PARP level was increased in kurarinone treated cells at 6.25, 12.5, and 25  $\mu\text{M}$  concentrations. Further, the change in cleaved caspase 3, Bcl-2 and Bcl-XL proteins in the presence of kurarinone revealed mitochondria and receptor mediated apoptosis induction in SCLC cells. Kurarinone increased the sub-G1 population of H1688 cells up to 60% at test concentrations. The phytochemical treatment at 3.125, 6.25, and 12.5  $\mu\text{M}$  concentrations increased the E-cadherin level and decreased the vimentin, N-cadherin, and MMP3/2/9 which indicates the epithelial-mesenchymal transition potential in kurarinone (Chung et al., 2019).

Activating transcriptional factor 4 (ATF4) is an important protein that senses the various stress in the cell (especially ER stress). After activation, it induces stress-relieving and apoptotic genes. Activation of ATF4 by pharmacological agents is a good strategy to target cancer. Nishikawa et al. (2019) reported the effect of kurarinone on ATF4 activation and the cytostatic effect of kurarinone in prostate cancer cells. Kurarinone was isolated from the acetone extract of the *S. flavescens*. A dose dependent anticancer activity was observed in a prostate cancer cell line (PC3) at 10–50  $\mu\text{M}$  concentration ( $\text{IC}_{50}$  24.7  $\mu\text{M}$ ). A 2.02 selectivity index score was obtained by analyzing the cytotoxic activity of kurarinone in PC3 and normal human diploid fibroblast (TIG3 cells). The index showed the high selectivity of kurarinone toward cancer cells. It showed ATF4 activation and increased expression of its downstream effectors TRB3 in a time (6 and 10 h) and dose (20 and 50  $\mu\text{M}$ ) dependent manner at the protein level in prostate cancer cell line (PC3). Kurarinone also increased the TRB3 promoter activity at test concentrations. Kurarinone induced ATF4 activation through the PERK-eIF2 $\alpha$  pathway, which was revealed by the activation of PERK by its phosphorylation in the presence of the phytochemical. Further, the cytostatic effect of kurarinone was observed in prostate cancer cells, which was evident by the increased p21 and p27 levels and decrease in cyclin D1 and cyclin A protein expression at 20 and 50  $\mu\text{M}$  concentration (Nishikawa et al., 2019). Recently, Liang et al. (2021) predicted the potential anticancer efficacy of the ingredients of “Compound Kushen Injection” used for lung cancer. The study utilized the network pharmacology approach to find the drug targets, pathway prediction, and protein-protein network analysis for the identified active ingredients including kurarinone (Liang et al., 2021). Pre-clinical anticancer studies on kurarinone from the year 2000 to date show indifferent cancer experimental models, which have




been summarized in **Figure 2A**. The effect of kurarinone on various hallmarks of cancer (**Figure 2B**) indicates its diversified mode of action in cancer cells. The various anticancer mechanism of kurarinone is depicted in **Figure 3**.

## Anti-Inflammatory and Immune Response

Chi et al. (2001) studied the effect of kurarinone on eicosanoid generating enzymes such as cyclooxygenase 1 and 2 (COX-1 and COX-2) as well as 5- and 12-lipoxygenase (5-LOX and 12-LOX) in bovine platelet and polymorphonuclear leukocytes and monocyte/macrophage cell line (RAW 264.7). Kurarinone inhibited the COX and LOX enzymes in micromolar concentrations. Kurarinone showed better efficacy against the COX-1 enzyme (Chi et al., 2001) (**Figure 4**). Kim et al. (2002) showed that kurarinone was not able to down-regulate the COX-2 induction in LPS treated RAW cells up to 25  $\mu\text{M}$  concentration. Han et al. (2010) studied the nitric oxide (NO) production, reactive oxygen species (ROS) generation, inflammatory cytokine expression, NF- $\kappa$ B activity, and MAP kinases phosphorylation of kurarinone in lipopolysaccharide (LPS) induced monocyte/macrophage cell line (RAW 264.7). The NO and ROS mediated stress modulates the cytokine production by regulating the NF- $\kappa$ B pathway. The NF- $\kappa$ B translocates to the nucleus and initiates the transcription of target genes responsible for different molecular events (such as stress-response, peptide/cytokine/chemokine secretion, apoptosis inhibitory proteins, etc.). Kurarinone decreased ROS production, NO radical generation, and iNOS protein expression in LPS induced RAW 264.7 cells at micromolar concentration. Similarly, kurarinone reduced the expression of LPS induced expression of inflammatory genes (CCL2, TNF- $\alpha$ , IL-1 $\beta$ , and iNOS) at mRNA level in 24 h treatment. Further, kurarinone decreased the LPS induced





phosphorylation of different MAP kinases (ERK1/2, JNK, and p38) in test cell lines and NF- $\kappa$ B activation (Han et al., 2010).

Sahlan et al. (2019) studied the *in vivo* anti-inflammatory potential of propolis from *Tetragronula sp.* and characterized the compounds present in it. The anti-inflammatory potential of the micro-capsulated propolis was studied in the carrageenan-induced rat's paw inflammation model. LC-MS/MS analysis of the sample revealed that the presence of kurarinone is an active ingredient in propolis. Kurarinone containing propolis produced significant *in vivo* anti-inflammatory potential (Sahlan et al., 2019). Chen et al. (2020) studied the mechanistic efficacy of *S. flavescens* ethanolic extract in dextran sodium sulfate-induced ulcerative colitis rats. Ulcerative colitis (UC) is an immunological disease; if not treated, it may lead to colon cancer. The different pharmacodynamics parameters related to UC were studied. The UHPLC-MS/MS based analysis of the test extract showed the presence of kurarinone in the extract. The study concluded that the compounds such as kurarinone can alter the UT-related pathophysiological conditions (colon length and healthiness of

colon tissue, bleeding, etc.) in an experimental rat model (Chen et al., 2020). Kim et al. (2013) studied the immune response inhibitory potential of kurarinone in psoriasis-like skin disease and contact dermatitis experimental chronic inflammatory skin models. The study showed that the phytochemical can decrease the expression of inflammatory molecules (cytokines/interleukins and inflammatory enzymes) and thereby inhibit the JAK/STAT signaling and T-cell receptor pathways. Besides, kurarinone also suppressed the inhibition of the differentiation of CD4(+) T cells in the experimental models. Xie et al. (2018) studied the clinical parameters such as inflammation, demyelination, T helper cells sub-population in sections of the spinal cord, and splenocytes of the multiple sclerosis experimental models. The study reported that kurarinone (100 mg/kg/day) has therapeutic potential against multiple sclerosis mainly by inhibiting Th1 and Th17 cellular proliferation and differentiation.

Nishikawa et al. (2020) studied the anti-inflammatory mode of action of kurarinone *in vitro* using RAW264.7 and HaCaT cells. Kurarinone showed KEAP1 (kelch-like ECH-associated protein

1) down regulation mediated Nrf2 stabilization in a dose dependent manner (at 20–50  $\mu$ M concentration). Translocation of Nrf2 to the nucleus results in the expression of antioxidant genes (such as heme oxygenase-1 or HO-1) which initiates the detoxification process. Moreover, the study revealed that kurarinone has the potential to inhibit the LPS induced inflammation in RAW264.7 by suppressing the inflammatory mediators through the HO-1 enzyme (Nishikawa et al., 2020). Recently, Tang et al. (2021) studied the effect of kurarinone and its mode of action in collagen induced arthritis mice model. The kurarinone treated experimental group showed decreased serum and paw tissue levels of TNF- $\alpha$ , IL-6, IFN- $\gamma$ , and IL-17A in collagen-induced arthritis (CIA) mice at 100 mg/kg/day dose. It increased the expression of antioxidant proteins (SOD and GSH-Px) and decreased the MDA production and hydrogen peroxide in paw tissues. Further, the study showed that kurarinone increased the Nrf2 and OH-1 protein expression and decreased the KEAP1 expression in the experimental mice. The study showed that kurarinone exerts the anti-inflammatory action by altering the Th1 and Th17 cell differentiation, increasing antioxidant level and alterations in the Nrf2 pathway in the arthritis animal model (Tang et al., 2021) (Figure 3).

### Effect on Drug Resistance

Choi et al. (1999) tested the anticancer efficacy of the sophora flavanone including kurarinone on P-glycoprotein (Pgp) expressing human colon cancer cell line (HCT15). The effect of kurarinone was also studied on the multi-drug resistance subline of the HCT15 cells (HCT15/CL02). They found that kurarinone showed less activity against HCT15/CL02 cells in comparison to HCT15 cells. Moreover, they reported that combining the treatment with the standard anticancer drug and Pgp inhibitor (Verapamil) also did not increase the cytotoxicity of kurarinone in the test cells. At non-toxic concentrations the kurarinone was not able to increase the paclitaxel mediated cytotoxicity as well as cytoplasmic accumulation of rhodamine 123 dye in the drug resistant cell line. The author concluded that the kurarinone has no effect on Pgp mediated drug resistance in colon cancer cells (Choi et al., 1999). Chen et al. (2005) studied the anti-bacterial efficacy in methicillin and vancomycin antibiotic resistant bacteria *Staphylococcus aureus* (MRSA) and *Vancomycin-resistant enterococci* (VRE), respectively. These two bacteria are among the most common causative agents for lethal hospital infections. They isolated the kurarinone from the roots of *S. flavescens* using HPLC and characterized the compound using NMR spectroscopy. Kurarinone showed 2  $\mu$ g/ml MIC against both tested drug-resistant bacteria. The author also reported the dose dependent anti-drug resistant potential in kurarinone against MRSA and VRE bacteria (Chen et al., 2005).

### Antimicrobial (Fungal, Yeast, Virus, Bacteria) Activity

Tan et al. (1996) isolated kurarinone from aqueous-acetone root extracts of *Gentiana macropphylla* (Family) using the LC-UV-

mass spectrometry method. They reported that kurarinone is active against plant pathogenic fungus and human pathogenic yeast, namely, *Cladosporium cucumerinum* and *Candida albicans*, respectively. The minimum inhibitory concentration (MIC) of kurarinone against the *C. cucumerinum* and *C. albicans* was 5  $\mu$ g. In the same study, Miconazole and Propiconazole standard growth inhibitors against *C. cucumerinum* and *C. albicans* showed 0.1 and 0.001  $\mu$ g MIC, respectively (Tan et al., 1996). Sohn et al. (2004) studied the antimicrobial activity of kurarinone (isolated from *S. flavescens* root) against bacteria (*Escherichia coli*, *Salmonella typhimurium*, *Staphylococcus epidermidis*, and *S. aureus*) and fungus (*Candida albicans* and *Saccharomyces cerevisiae*) using micro-dilution method-based MIC calculation. Kurarinone showed 60 and 100  $\mu$ g/ml MIC against all the test fungus and bacteria, respectively. The antibacterial activity was compared with respective standard antibacterial and antifungal compounds such as Ampicillin, Erythromycin, Amphotericin B, Miconazole, and 5-Fluorocytosine (Sohn et al., 2004). Ryu et al. (2008) reported antibacterial activity of kurarinone against Gram-positive/negative bacteria using the paper-disk diffusion method. The *Bacillus subtilis*, *Bacillus cereus*, *Staphylococcus aureus*, and *Escherichia coli* were used to assess the antibacterial activity. The study was performed on the kurarinone isolated from the chloroform fraction of *S. flavescens* methanolic root extract. Kurarinone showed potential antibacterial against *B. subtilis*, *B. cereus*, and *S. aureus* ( $\approx$ 15 zone of inhibition, ZOI). Kurarinone did not show inhibitory potential against *E. coli*. The antibacterial activity was compared with the standard antibacterial agent, Ampicillin (Ryu et al., 2008). In an interesting study, Chong et al. (2013) reported the antibacterial activity of kurarinone nanoparticles deposited onto a filter material. The antimicrobial potential durability and nanoparticles morphology was assessed over a time period of 5 months. The study was designed to tackle the toxicity and infection related problems that arise from airborne biological particles such as bacteria. The ethanolic solution of freeze-dried *S. flavescens* whole plant powder and Gram-positive/negative bacteria (Gram-positive *Staphylococcus epidermidis* and *Escherichia coli*) were used for the study. The bacterial inactivation percentage was calculated by using the  $(\text{CFU}_{\text{experiment}}/\text{CFU}_{\text{control}}) \times 100$ .  $\text{CFU}_{\text{experiment}}$  and  $\text{CFU}_{\text{control}}$  represented the concentration of bacterial colonies obtained from the test and control groups, respectively. The major components in the ethanolic fraction of the test material were studied, and kurarinone was one of them. The study showed that kurarinone chemical degradation was significantly lower in comparison to other test compounds over the 5-month period. The study established the use of natural product nanoparticles for the antimicrobial potential of filters (Chong et al., 2013).

Recently, Min et al. (2020) reported the anti-human coronavirus infection potential in kurarinone. The human coronavirus-OC43 (HCoV-OC43) infected lung fibroblast cell line (MRC-5) was utilized to study the anti-corona virus infection. The cellular toxicity, quantification of virus RNA copy number, viral protein expression, quantification of cytokine at mRNA level, and other parameters were studied in

transfected MRC-5 cells treated with kurarinone. The test compound inhibited the growth of virus infected fibroblast cell line at  $\approx 3.5 \mu\text{M}$   $\text{IC}_{50}$  concentration (Min et al., 2020). The cells were incubated with kurarinone at  $3.5 \mu\text{M}$  for 4 days and then studied for the virus-induced cytopathic effect using light microscopy. The results were compared with the non-treated and remdesivir treated groups. The result revealed promising potential in kurarinone against virus-induced cytopathic effect in transfected fibroblast. qRT-PCR and Western blot analysis revealed that kurarinone significantly reduced the expression of viral proteins at mRNA and protein levels in the transfected cells. Further, the time-of-addition assay showed virus-induced cytopathic effect of kurarinone was significant (in co-administered and post-viral administered treatment) (Min et al., 2020). Impairment in autophagy in host cells is an important phenomenon in virus-induced cytopathic effect. Studies showed that the kurarinone has potential to mitigate the virus-induced autophagy by modulating the expression of LC3-II/LC3-I ratio at  $5 \mu\text{M}$  (Min et al., 2020).

### Antioxidant Activity

Jung et al. (2004) first assessed the antioxidant potential of kurarinone isolated from the ethanolic fraction of the methanol extract of *Albizia julibrissin* (Leguminosae). The antioxidant potential was assessed using 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity (Jung et al., 2004). Later, Piao et al. (2006) reported *in vitro* radical scavenging potential of kurarinone in biochemical and cell culture experiments. The kurarinone was isolated from aqueous, methylene chloride, and butanol fractions of *S. flavescens* root methanol extract using bioactivity-guided fractionation and isolation approach. The radical scavenging potential was tested using DPPH radical scavenging assay. The protective efficacy of kurarinone against free radical (2,2'-azobis(2-amidinopropane) dihydrochloride or (AAPH)-induced damage in kidney cells (LLC-PK<sub>1</sub>). Kurarinone (butanol fraction) showed potential dose dependent DPPH radical scavenging activity ( $7.73 \mu\text{g/ml}$   $\text{IC}_{50}$ ). The butanol fraction produced dose dependent protective efficacy in AAPH induced oxidative damage in LLC-PK<sub>1</sub> cells. The non-treated and AAPH treated cells were considered as control experimental setup to compare the results. AAPH decreased the LLC-PK<sub>1</sub> cell viability by 60%. Kurarinone treatment restored the cell viability by 70–90% at  $5\text{--}50 \mu\text{g/ml}$  concentration (Piao et al., 2006).

Jeong et al. (2008) studied the copper-induced low-density lipoprotein (LDL) oxidation of *S. flavescens* root isolated kurarinone. The LDL was isolated from human plasma and oxidized with copper to produced oxidized LDL. Conjugate diene formation, malondialdehyde (MDA) estimation, and REM (relative electrophoretic mobility) the assay was performed to assess the anti-oxidative effect of kurarinone in cu-induced LDL oxidation model. Dose and time dependent decreased MDA ( $\text{IC}_{50}$   $14.5 \mu\text{M}$ ) and diene production (at  $5 \mu\text{M}$ ), respectively, were observed in a kurarinone treated experimental group (Jeong et al., 2008). REM assay showed that at higher concentrations ( $20\text{--}80 \mu\text{M}$ ) kurarinone inhibited the formation of oxidized LDL (from wild type non-oxidized

LDL). Further, the effect of kurarinone on LDL oxidation was also studied by assessing the fragmentation of lipoprotein apoB-100 using the SDS-PAGE technique. Results showed 56–89% protection against apoB-100 oxidative modification at  $40\text{--}160 \mu\text{M}$  concentration in SDS-PAGE based assay. The study revealed the apoB-10 fragmentation protection against LDL oxidation (Jeong et al., 2008). Zhou et al. (2018) assessed the antioxidant potential of kurarinone containing *S. flavescens* in ultrasonic-assisted optimized isolated flavonoid fraction. The HPLC analysis of the fraction revealed the presence of kurarinone as one of the major constituents of *S. flavescens* extract. The fraction was subjected to test the antioxidant potential in terms of DPPH radical and hydroxyl radical scavenging activity. Dose dependent antioxidant activity was observed with  $0.984$  and  $1.084 \text{ mg/g}$   $\text{IC}_{50}$  in DPPH and OH radical scavenging assay, respectively (Zhou et al., 2018).

### Neuroprotective Efficacy

Jeong et al. (2008) studied the neuroprotective efficacy of flavones isolated from *S. flavescens* in glutamate induced experimental model. The glutamate mediated neurotoxicity (oxidative stress) was induced in immortalized mouse hippocampal cell line (HT22). The heme oxygenase (HO)-1 activity and ROS generation were studied in *S. flavescens* flavones treated HT22 cells. Kurarinone did not show the effect on (HO)-1 activity and ROS generation in the experimental setup (Jeong et al., 2008). Park et al. (2009) studied neuroprotective effects of *S. flavescens* ethyl acetate extract (alkaloid free) by studying its efficacy against focal cerebral ischemia (FCI) in the experimental rat model. HPLC analysis of the solvent-portioned extract (by using various solvents such as water, hexane, etc.) revealed  $\approx 46\%$  kurarinone in the test material. The middle cerebral artery occlusion (MCAO) method was to induce FCI in the Sprague-Dawley rats. The extract showed dose dependent decrease in the sodium nitroprusside induced cell mortality in SH-SY5Y (neuronal) cells. Kurarinone containing test extract pretreatment ( $0.2\text{--}10 \mu\text{g/ml}$ ) increased the apoptotic population (by modulating the protein expression of caspase-3 and extent of DNA fragmentation) which was decreased in the sodium nitroprusside treated group. After the satisfactory results in the *in vitro* study, the author studied the neuroprotective efficacy of the test sample in the MCAO model. Results showed that kurarinone containing test extract significantly reduced the severity of neurological deficits in the experimental rats (Park et al., 2009).

### Channel and Transporter Activity Modulation

Voltage-gated  $\text{Ca}^{2+}$  channel modulates the concentration of calcium ions into the cells by checking their passage across the cell membrane and thereby affect muscle contraction. Yamahara et al. (1990) studied the muscle relaxation potential of *S. flavescens* root methanolic (MT) and ethanolic (ET) fractions in the thoracic aorta of rabbits and rats. The potassium chloride ( $50 \text{ mM}$ ) was used to induce contraction in the test sample and then the relaxation efficacy of *S. flavescens* root fractions was



studied. The results were compared with the papaverine ( $10^{-4}$  M) induced contraction (considered as 100%). The MT and ET fractions at 25–50  $\mu\text{g/ml}$  concentration exert 40–60% muscle relaxation. After portioning the ET fraction in butanol, water, and ET fractions, the ET fraction showed 100% muscle relaxation. To identify the active ingredient the ET fraction was further sub-fractionated into nine parts. Out of which the second sub-fraction was identified as kurarinone, and showed about 100% muscle relaxation in rabbit and rat aorta (Komatsu et al., 1970; Yamahara et al., 1990).

Sodium-glucose cotransporter (SGLT) is known to absorb/re-absorb the glucose molecules into the cells. The SGLT1 and SGLT2 are responsible for the absorption of dietary glucose and reabsorption of body glucose in the proximal tubule, respectively. The inhibition of the SGLT transporter is an attractive target for type 2 diabetes. Sato et al. (2007) studied the SGLT1 and SGLT2 transporter inhibition potential of *S. flavescens* root extracts. Initially, the methanolic extract was portioned into water and ethyl alcohol. The alcoholic fraction was further sub-fractionated into 10 fractions out of which fraction 5 yielded kurarinone. To study the SGLT inhibitory potential of the isolated compounds, [ $^{14}\text{C}$ ]methyl- $\alpha$ -D-glucopyranoside uptake was assessed in hSGLT1 or hSGLT2 expressing monkey kidney derived fibroblast like cells (COS-1). At 50  $\mu\text{M}$ , kurarinone containing fraction showed  $\approx 100\%$  SGLT1 and SGLT2 inhibition efficacy. In a further experiment, kurarinone exerted 50% inhibitory potential against SGLT1 and SGLT2 with  $\text{IC}_{50}$  of 10.4 and 1.7  $\mu\text{M}$ , respectively (Sato et al., 2007).

Gamma-aminobutyric acid type A ( $\text{GABA}_A$ ) receptors are involved in neurotransmission inhibition through the influx of calcium ions in response to the binding of  $\gamma$ -aminobutyric acid to the receptor.  $\text{GABA}_A$  receptor inhibitors are used to treat different neuronal pathophysiological conditions. Yang et al. (2011) studied the  $\text{GABA}_A$  receptors potentiation of kurarinone in *Xenopus* oocytes. The ethanol extract of *S. flavescens* root was prepared and the micro fractionation was done using HPLC to obtain 22 fractions. The kurarinone was identified in fraction 9 and showed maximum potentiation (100% at 10  $\mu\text{M}$  concentration) of  $\text{GABA}_A$  receptors, which were transiently expressed in stages I-IV *Xenopus* oocytes (Yang et al., 2011).

The  $\text{BK}_{\text{Ca}}$  (large conductance Ca-activated K-channel) channel is involved in the relaxation process of the urinary bladder smooth muscle. In over-reactive bladders, the channel possesses therapeutic target potential to control micturition frequency (Lee et al., 2016). Lee et al. (2018) screened  $\approx 800$  natural compounds for their  $\text{BK}_{\text{Ca}}$  potentiation efficacy by using cell-based fluorescence assay in hyperactive mutant  $\text{BK}_{\text{Ca}}$  channel expressing AD-293 cells (derived from human embryonic kidney cells). At 5  $\mu\text{M}$  kurarinone increased the  $\text{BK}_{\text{Ca}}$  channel activity as evident by the increase in fluorescence. The mechanistic study revealed that the kurarinone stabilizes the open conformation of the channel. Moreover, the study also reported that the kurarinone treatment decreases the bladder contraction in rats having over-activated urinary bladders and thereby decreased the micturition frequency (Lee et al., 2018).

In diabetic patients, use of SGLT inhibitors may create a urinary tract infection (UTI) problem as the increased glucose concentration in the urine favors bacterial growth. The bacteria used to attach with the host cells by Type 1 pili (which possess FimH protein). Mashraqi et al. (2021) studied the human SGLT transporter and bacterial FimH protein inhibition potential of natural flavonoids using computer aided drug discovery approach. It has been postulated that the natural compound possessing the inhibitory action against both targets may be used as potential anti-diabetic agents having lesser side effects. In the study kurarinone showed potential binding ( $-7$  kcal/mole) against an SGLT transporter but moderate binding (about  $-4$  kcal/mole) with the FimH protein (Mashraqi et al., 2021).


## Tyrosinase Inhibition Potential

Tyrosinase enzyme is an attractive target for disease associated with local hyperpigmentation as well as in the cosmetic industry for skin whitening. The enzyme modulates the melanin biosynthesis and possesses L-tyrosine hydroxylase and L-dopa oxidase activities. Son et al. (2003) prepared *S. flavescens* root methanol extract, and after portioning (using water, dichloromethane, and ethyl acetate (ET)) the fractions were tested for tyrosinase inhibitory activity. The most potent ET fraction was further fractionated in eight sub-fractions. The kurarinone was identified in one of the sub-fractions and showed potent *in vitro* tyrosinase potential with 1.3  $\mu\text{M}$   $\text{IC}_{50}$  concentrations (Son et al., 2003). In a different study, Kim et al. (2003) reported significant dose dependent mushroom tyrosinase inhibitory efficacy ( $\approx 100\%$ ) in kurarinone at 1–50  $\mu\text{M}$  concentration. Ryu et al. (2008) studied the tyrosinase inhibition potential of kurarinone in the *S. flavescens* methanol extract isolated compounds. The result showed that kurarinone inhibited ( $\text{IC}_{50}$  2.2  $\mu\text{M}$ ) L-tyrosine oxidation in a dose dependent manner but did not fully inhibit the tyrosinase enzyme activity. Enzyme kinetics study showed that kurarinone decreased the  $V_{\text{max}}$  value with increasing concentration. The mushroom tyrosinase enzyme inhibition assay revealed kurarinone as a noncompetitive inhibitor with 4.1  $\mu\text{M}$  inhibition constant (Ryu et al., 2008).

## Other Pharmacological Potential

The accumulation of triacylglycerol in the body is related to several pathophysiological conditions such as coronary heart disease, obesity, diabetes, and hypertriglyceridemia. Diacylglycerol acyltransferase (DGAT) is a committed step in triacylglycerol synthesis, which makes it a suitable target for the management of the abovementioned disease in patients. Chung et al. (2004) studied the DGAT inhibitory potential of kurarinone. In the spectrophotometric method, kurarinone showed dose dependent DGAT inhibition potential with 10.9  $\mu\text{M}$   $\text{IC}_{50}$  in microsomal rat liver fractions. Further, the study on Raji cells showed that kurarinone inhibit free long chain in fatty acid based lipid synthesis at 3–10  $\mu\text{M}$  concentrations (Chung et al., 2004). Protein tyrosine phosphatase 1B is known to inhibit the insulin signaling pathway and thus possess potential as an anti-diabetic therapeutic target. Sasaki et al. (2014) reported that kurarinone inhibited the protein with 41.68  $\mu\text{M}$   $\text{IC}_{50}$ .





De Naeyer et al. (2004) studied the estrogenic potential of kurarinone. The kurarinone was obtained from the bioactivity-guided sub-fractionation of the *S. flavescens* phenolic extract. The activity was studied in the Ishikawa Var-I bioassay and yeast model. Kurarinone showed potent dose dependent estrogenic activity among the test compounds with 4.6 and 1.6  $\mu$ M EC<sub>50</sub> in the yeast screen and Ishikawa Var-I bioassay (De Naeyer et al., 2004).

Glucosidase is an important enzyme related to digestion of carbohydrates, glycoprotein synthesis, and degradation of glycoconjugates. Glucosidase inhibitors are well studied for type 2 diabetes, cancer, and other diseases. Kim et al. (2006) studied the glycosidase inhibition potential of kurarinone isolated from *S. flavescens* root extract and sub-fractionation. The glycosidase activity was assessed for  $\alpha$ -glucosidase,  $\beta$ -galactosidase,  $\alpha/\beta$  amylase, and invertase enzymes. Kurarinone showed about 99 and 54%  $\alpha$ -glucosidase and  $\beta$  amylase inhibition potential with 45 and 980  $\mu$ M IC<sub>50</sub> concentrations, respectively. Further, the enzyme kinetics study showed that kurarinone is a noncompetitive inhibitor of  $\alpha$ -glucosidase with 6.8  $\mu$ M  $K_i$  (inhibitory constant) (Kim et al., 2006).

Gao et al. (2007) studied the effect of kurarinone on renal trans-differentiation and interstitial fibrosis in the experimental rat model. The renal interstitial fibrosis rat model was utilized and kurarinone treatment was done at 100 mg/kg body weight. The serum biomarkers (such as creatinine, protein content, albumin, blood urea nitrogen, etc.), pathological markers (in renal tissue), and molecular markers (TGF- $\beta$ 1,  $\alpha$ SMA, Smad3, collagen I, etc.) of the disease were studied using appropriate techniques. The kurarinone treated experimental group showed significant down regulated TGF- $\beta$ 1 and collagen I expressions. The study

concluded that kurarinone may exert the anti-fibrosis effect through Smad3 down expression (Gao et al., 2007).

Aldose reductase (AR) an NADPH-dependent oxidoreductase converts excess glucose in sorbitol and ultimately in fructose. Later, their accumulation hampers the normal metabolic process and creates complications in diabetic patients. Excess amounts of sorbitol and fructose also produce reactive dicarbonyl species much related to AGE (advanced glycation end products) formation. Jung et al. (2008) reported the AR (rat lens and human recombinant ARs) and AGE inhibition potential in kurarinone using the spectrophotometric method. Kurarinone showed about 31–65% rat lens AR inhibition potential at 0.4–2  $\mu$ g/ml concentration with 2.99  $\mu$ M IC<sub>50</sub>. The human recombinant AR inhibition potential was assessed at 1 and 5  $\mu$ g/ml, which showed 45 and 75% inhibition of the AR with 3.81  $\mu$ M IC<sub>50</sub>. Kurarinone did not exert the AGE inhibitory efficacy (Jung et al., 2008).

Phytochemicals are known to increase osteoblastic cell proliferation and alkaline phosphate activity both *in vitro* and *in vivo*. Plant product-based management of bone associated diseases such as osteoporosis is a cost-effective strategy. Keeping these facts in mind, Wang et al. (2011) studied the osteogenic effect of flavonoids isolated from *Drynaria fortune*. The study isolated kurarinone from the plant extract which did not show the osteogenic effect at all the test concentrations (10–1,000 nm) in the osteoblastic UMR 106 cells. At higher concentrations, kurarinone increased the ALP activity about 74% (Wang et al., 2011). Xanthine oxidase is an important drug target used for gout, hyperuricemia, ischemic tissue/vascular injuries, inflammation related diseases, and myocardial infarction. Suzuki et al. (2013) studied the xanthine oxidase inhibition potential of kurarinone. The result showed that kurarinone was active against the enzyme only at a higher concentration (100  $\mu$ M) (Suzuki et al., 2013).

Human carboxylesterases 2 (hCE2) is an important type I xenobiotic metabolism enzyme involved in the ester group metabolism. It detoxifies several environmental toxins in the body as well as hydrolyzes the ester group present in several therapeutic agents. Song et al. (2019) reported the hCE2 inhibitory potential of kurarinone *in vitro*. Kurarinone showed more than 90% hCE2 inhibition potential with 1.46  $\mu$ M IC<sub>50</sub> concentration. The activity was dose dependent. Kurarinone was found to be an uncompetitive type inhibitor of hCE2 with 1.73  $\mu$ M inhibition constant ( $K_i$ ) (Song et al., 2019).

## Bioavailability, Metabolism, and Toxicity

*Sophora flavescens* is a medicinal herb and possesses hepatoprotective phytochemicals. Zhixue capsule, a Chinese herbal prescription, encompasses *S. flavescens* extract. The capsule was found to exert dose dependent hepatotoxicity in primary rat hepatocytes (Yu et al., 2013). The *S. flavescens* possess hepatoprotective phytochemicals, so how can it show hepato-toxicity? To solve this puzzle, Yu et al. (2013) studied the hepatotoxicity of the *S. flavescens* phytoconstituents in experimental rats. The rats were administered with the *S. flavescens* methanol extract at 1.25 and 2.5 g/kg body weight, twice a day. The treatment was carried out for 3 days. After the treatment, serum alanine transaminase (ALT), AST, and liver histopathology were studied. The result showed an increased concentration of the enzyme markers and

damaged liver histology. The extract was sub-fractionated into eight fractions using the semi-preparative HPLC technique. The hepatotoxic effect of kurarinone (subfraction) in rat primary hepatocyte and HL-7702 cells (at 50, 100, and 200  $\mu\text{g/ml}$  concentration) showed significant toxicity ( $\approx 30$  and 48  $\mu\text{M}$   $\text{IC}_{50}$ , respectively) (Yu et al., 2013). Jiang et al. (2017) studied the mechanism of kurarinone toxicity in *in vitro* and *in vivo* experimental models. The rats were administered with 1.25 and 2.5 g/kg kurarinone for 14 days. The *in vitro* test in HEK293 cells showed that kurarinone glucuronide get internalized into the cells through OATP1B3 transporter, which is responsible for the entry of therapeutic molecules in the hepatic cells. Inside the hepatocyte, kurarinone inhibits the PPAR- $\alpha$  pathway and reduces L-carnitine which leads to lipid accumulation and liver cell injury (Jiang et al., 2017).

Zhang et al. (2015) developed a method to determine the kurarinone concentration in biological fluids (rat plasma) using UPLC-MS/MS technique. The kurarinone was administered at a dose of 10 mg/kg body weight. The result showed that kurarinone was found for about 1 h in the plasma; after that, the concentration decreased very fast and becomes zero at the sixth hour (Zhang et al., 2015). A similar study was performed by Yang et al. (2016), which administered a higher amount of kurarinone (25 and 500 mg/kg by weight) and the stability in rat plasma was monitored for 12 h (Yang et al., 2016). In a similar but different study, Huang et al. (2020) developed a UPLC-MS/MS based method to detect the kurarinone levels in dog plasma. In this study, kurarinone was administered at 2 and 20 mg/kg body weight, and the blood plasma level was monitored for 25 h (Huang et al., 2020).

*S. flavescens* extract has been reported for its effect on xenobiotic metabolism enzyme modulation. For the first time, Qin et al. (2020) studied the interaction of kurarinone with cytochrome P450 and UDP-glucuronosyl transferase enzymes in the liver microsomes and recombinant human supersomes. The result showed that kurarinone inhibited UDP-glucuronosyl transferase (UGT1A1/A6) and cytochrome P450 (CYP2C9, 1A2, and 2D6) effectively at 100  $\mu\text{M}$  concentrations (Qin et al., 2020). In a different study, Zhang et al. (2016) reported the mode of kurarinone metabolism in human liver microsomes. The study showed that it is metabolized in liver microsomes by the glucuronidation detoxification pathway. The study provided important information about the safe usage of kurarinone as a therapeutic molecule.

## Clinical Study and Patents

In an important clinical study, Pan et al. (2005) studied the combinatorial effect of kurarinone and interferon alpha-1b (IFN $\alpha$ -1b) in chronic hepatitis B patients. The kurarinone and IFN $\alpha$ -1b were added with the conventional hepatitis B treatment to the patients (Group A). Further, Groups B and C represented the addition of kurarinone and IFN $\alpha$ -1b alone with the treatment, respectively. The treatment was carried out for 6 months and during the next 6 months follow up of the patients was carried out to study the disease associated pathological markers such as liver histology, tissue, and serum TGF- $\beta$  levels, ALT, etc. The result

showed that only Group A significantly lowered the liver fibrosis scores and mitigated the pathophysiological markers (Pan et al., 2005). Natural formulation containing kurarinone has been patented for its therapeutic efficacy against hepatitis and cancer (patent number CN1970001B and CN1961898A, respectively). The fact substantiates the therapeutic efficacy of kurarinone.

## CONCLUSION AND FUTURE PROSPECTS

An extensive literature survey on kurarinone (from its first isolation in 1970 to date) revealed the potent therapeutic potential in kurarinone against various disease/ailments. The present review summarizes the chemoprevention and other pharmacological activities of kurarinone (a natural flavanone). It exhibits cell proliferation inhibition, cell cycle arrest, apoptosis induction, anti-metastasis, and stress-induced cytotoxicity in different cancer cells. Kurarinone is an important ingredient of several Chinese medicinal products. The present review activities justify the traditional use of kurarinone in the medicinal system. Although some authors reported hepatotoxicity of kurarinone, but in most of the studies authors showed cancer cell selectivity property in it. Further, a clinical study also showed the non-toxic therapeutic property in kurarinone. Thus, the targeted study should be designed to study the bioavailability and toxicity profile of kurarinone in a pre-clinical and clinical setup. Most of the *in vivo* mechanistic anticancer potential was studied in the lung cancer experimental model, leaving other devastating cancers such as breast, colon, etc. This creates a large thrust area for further research in other cancers at pre-clinical and clinical levels. The literature is silent about the effect of kurarinone on other hallmarks of cancer such as angiogenesis, cancer stemness, etc. Experimental studies showed that kurarinone has the potential to inhibit NF- $\kappa\text{B}$  activation directly and indirectly (by lowering TNF- $\alpha$  induction) in disease models such as inflammatory disease (collagen-induced arthritis) and cancer. In arthritis, higher expression of inflammatory molecules (interleukins and TNF- $\alpha$ ) activates the NF- $\kappa\text{B}$  inflammatory pathway which results in the disease progression. In cancer, NF- $\kappa\text{B}$  activation is known to inhibit the apoptotic process which results in cancer cell survival. Thus, the literature indicates that the inhibition of the NF- $\kappa\text{B}$  mediated pathway is one of the important mechanisms behind the pharmacological potential of kurarinone. The pharmacological potential of the phytochemical in other diseases that are associated with the NF- $\kappa\text{B}$  inflammatory pathway should be studied in appropriate *in vitro* and *in vivo* models. Furthermore, the literature showed that kurarinone can inhibit NF- $\kappa\text{B}$ , JAK/STAT, and Akt pathways in different disease experimental models. These pathways are well-known therapeutic targets for cancer and inflammatory diseases. Activation of JAK/STAT, and Akt pathways are well correlated with the tumor initiation, progression, and metastasis. Inflammatory

molecules are known to up-regulate the notch signaling pathway which results in various pathological conditions including cancer. Thus, kurarinone might inhibit the notch signaling mediated pathological effects by regulating the NF- $\kappa$ B inhibition mediated inflammatory response. Although the literature showed antioxidant potential in kurarinone, its nutraceutical and/or food supplementation potential has not yet been established. Thus, the *in vitro* and *in vivo* studies regarding nutraceutical/food supplementation potential of the phytochemicals are very much required. The results of the studies might open the transformation of kurarinone from a therapeutic molecule to a potential nutraceutical. Moreover, the metabolism and xenobiotic metabolic enzyme inhibition mediated in-depth efficacy in the associated disease model have not been fully investigated well. Overall, the present study provides a comprehensive update on the therapeutic potential of kurarinone, which may foster the discovery and development of novel therapeutic agents for the treatment of various diseases including cancer.

## REFERENCES

Berghe, W. V., De Naeyer, A., Dijsselbloem, N., David, J. P., De Keukeleire, D., and Haegeman, G. (2011). Attenuation of ERK/RSK2-Driven NF $\kappa$ B Gene Expression and Cancer Cell Proliferation by Kurarinone, a Lavandulyl Flavanone Isolated from *Sophora flavescens* Ait. Roots. *Endocr. Metab. Immune. Disord. Drug Targets* 11, 247–261. doi:10.2174/187153011796429790

Chen, L., Cheng, X., Shi, W., Lu, Q., Go, V. L., Heber, D., et al. (2005). Inhibition of Growth of Streptococcus Mutans, Methicillin-Resistant *Staphylococcus aureus*, and Vancomycin-Resistant Enterococci by Kurarinone, a Bioactive Flavonoid Isolated from *Sophora flavescens*. *J. Clin. Microbiol.* 43, 3574–3575. doi:10.1128/JCM.43.7.3574-3575.2005

Chen, L., Huang, X., Wang, H., Shao, J., Luo, Y., Zhao, K., et al. (2020). Integrated Metabolomics and Network Pharmacology Strategy for Ascertaining the Quality Marker of Flavonoids for *Sophora flavescens*. *J. Pharm. Biomed. Anal.* 186, 113297–113313. doi:10.1016/j.jpba.2020.113297

Chi, Y. S., Jong, H. G., Son, K. H., Chang, H. W., Kang, S. S., and Kim, H. P. (2001). Effects of Naturally Occurring Prenylated Flavonoids on Enzymes Metabolizing Arachidonic Acid: Cyclooxygenases and Lipoxygenases. *Biochem. Pharmacol.* 62, 1185–1191. doi:10.1016/s0006-2952(01)00773-0

Choi, S. U., Kim, K. H., Choi, E. J., Park, S. H., Lee, C. O., Jung, N. P., et al. (1999). P-glycoprotein (Pgp) Does Not Affect the Cytotoxicity of Flavonoids from *Sophora flavescens*, Which Also Have No Effects on Pgp Action. *Anticancer. Res.* 19, 2035–2040.

Chong, E. S., Hwang, G. B., Nho, C. W., Kwon, B. M., Lee, J. E., Seo, S., et al. (2013). Antimicrobial Durability of Air Filters Coated with Airborne *Sophora flavescens* Nanoparticles. *Sci. Total Environ.* 444, 110–114. doi:10.1016/j.scitotenv.2012.11.075

Chung, M. Y., Rho, M. C., Ko, J. S., Ryu, S. Y., Jeune, K. H., Kim, K., et al. (2004). *In Vitro* Inhibition of Diacylglycerol Acyltransferase by Prenylflavonoids from *Sophora flavescens*. *Planta. Med.* 70, 258–260. doi:10.1055/s-2004-815545

Chung, T. W., Lin, C. C., Lin, S. C., Chan, H. L., and Yang, C. C. (2019). Antitumor Effect of Kurarinone and Underlying Mechanism in Small Cell Lung Carcinoma Cells. *Oncotargets Ther.* 12, 6119–6131. doi:10.2147/OTT.S214964

De Naeyer, A., Vanden Berghe, W., Pocock, V., Milligan, S., Haegeman, G., and De Keukeleire, D. (2004). Estrogenic and Anticarcinogenic Properties of Kurarinone, a Lavandulyl Flavanone from the Roots of *Sophora flavescens*. *J. Nat. Prod.* 67, 1829–1832. doi:10.1021/np040069a

Gao, H. Y., He, X. F., and Shao, J. F. (2007). Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi = Chinese. *J. Integrat. Trad. Western. Med.* 27, 535–539.

## AUTHOR CONTRIBUTIONS

SK designed the study, drafted and wrote the article. PK, KP, AS, and MS searched literature and compiled the data. KP, AS, and PK prepared the figures and tables. All authors read and approved the final article. HT reviewed the article critically.

## ACKNOWLEDGMENTS

AS acknowledges CSIR, India for CSIR-Senior Research Fellowship. PK acknowledges ICMR, India for Senior Research Fellowship [File No. 5/3/8/82/ITR-F/2020-ITR]. MS (File No. 5/3/8/80/ITR-F/2020-ITR) and KP acknowledge DBT and ICMR, India, respectively, for Senior Research Fellowship, respectively. SK acknowledges DST for providing Departmental DST-FIST grant to the Department of Biochemistry, Central University of Punjab, India.

Guo, R., Zhang, X., Su, J., Xu, H., Zhang, Y., Zhang, F., et al. (2018). Identifying Potential Quality Markers of Xin-Su-Ning Capsules Acting on Arrhythmia by Integrating UHPLC-LTQ-Orbitrap, ADME Prediction and Network Target Analysis. *Phytomedicine* 44, 117–128. doi:10.1016/j.phymed.2018.01.019

Han, J., Sun, M., Cui, Y., Wang, T., Zhang, W., Guo, M., et al. (2007). Kushen Flavonoids Induce Apoptosis in Tumor Cells by Inhibition of NF- $\kappa$ B Activation and Multiple Receptor Tyrosine Kinase Activities. *Phytother. Res.* 21, 262–268. doi:10.1002/ptr.2065

Han, J. M., Jin, Y. Y., Kim, H. Y., Park, K. H., Lee, W. S., and Jeong, T. S. (2010). Lavandulyl Flavonoids from *Sophora flavescens* Suppress Lipopolysaccharide-Induced Activation of Nuclear Factor- $\kappa$ B and Mitogen-Activated Protein Kinases in RAW264.7 Cells. *Biol. Pharm. Bull.* 33, 1019–1023. doi:10.1248/bpb.33.1019

He, C. M., Cheng, Z. H., and Chen, D. F. (2013). Qualitative and Quantitative Analysis of Flavonoids in *Sophora tonkinensis* by LC/MS and HPLC. *Chin. J. Nat. Med.* 11, 690–698. doi:10.1016/S1875-5364(13)60081-3

Huang, Y., Lin, H., Chen, Y., and Huang, X. (2020). Pharmacokinetic and Bioavailability Study of Kurarinone in Dog Plasma by UHPLC-MS/MS. *Biomed. Chromatogr.* 34, e4945. doi:10.1002/bmc.4945

Jeong, G. S., Li, B., Lee, D. S., Byun, E., An, R. B., Pae, H. O., et al. (2008). Lavandulyl Flavonones from *Sophora flavescens* Protect Mouse Hippocampal Cells against Glutamate-Induced Neurotoxicity via the Induction of Heme Oxygenase-1. *Biol. Pharm. Bull.* 31, 1964–1967. doi:10.1248/bpb.31.1964

Jiang, P., Zhang, X., Huang, Y., Cheng, N., and Ma, Y. (2017). Hepatotoxicity Induced by *Sophora flavescens* and Hepatic Accumulation of Kurarinone, a Major Hepatotoxic Constituent of *Sophora flavescens* in Rats. *Molecules* 22, 1809. doi:10.3390/molecules22111809

Jung, H. A., Jeong, D. M., Chung, H. Y., Lim, H. A., Kim, J. Y., Yoon, N. Y., et al. (2008). Re-evaluation of the Antioxidant Prenylated Flavonoids from the Roots of *Sophora flavescens*. *Biol. Pharm. Bull.* 31, 908–915. doi:10.1248/bpb.31.908

Jung, M. J., Kang, S. S., Jung, H. A., Kim, G. J., and Choi, J. S. (2004). Isolation of Flavonoids and a Cerebroside from the Stem Bark of *Albizia julibrissin*. *Arch. Pharm. Res.* 27, 593–599. doi:10.1007/BF02980155

Kang, T. H., Jeong, S. J., Ko, W. G., Kim, N. Y., Lee, B. H., Inagaki, M., et al. (2000). Cytotoxic Lavandulyl Flavonones from *Sophora flavescens*. *J. Nat. Prod.* 63, 680–681. doi:10.1021/np990567x

Kim, B. H., Na, K. M., Oh, I., Song, I. H., Lee, Y. S., Shin, J., et al. (2013). Kurarinone Regulates Immune Responses Through Regulation of the JAK/STAT and TCR-Mediated Signaling Pathways. *Biochem. Pharmacol.* 85, 1134–1144. doi:10.1016/j.bcp.2013.01.005

Kim, D. W., Chi, Y. S., Son, K. H., Chang, H. W., Kim, J. S., Kang, S. S., et al. (2002). Effects of Sophoraflavanone G, a Prenylated Flavonoid from *Sophora flavescens*,



- on Cyclooxygenase-2 and *In Vivo* Inflammatory Response. *Arch. Pharm. Res.* 25, 329–335. doi:10.1007/BF02976635
- Kim, J. H., Ryu, Y. B., Kang, N. S., Lee, B. W., Heo, J. S., Jeong, I. Y., et al. (2006). Glycosidase Inhibitory Flavonoids from *Sophora flavescens*. *Biol. Pharm. Bull.* 29, 302–305. doi:10.1248/bpb.29.302
- Kim, S. J., Son, K. H., Chang, H. W., Kang, S. S., and Kim, H. P. (2003). Tyrosinase Inhibitory Prenylated Flavonoids from *Sophora flavescens*. *Biol. Pharm. Bull.* 26, 1348–1350. doi:10.1248/bpb.26.1348
- Komatsu, M., Tomimori, T., Hatayama, K., and Mikuriya, N. (1970). Studies on the Constituents of *Sophora* Species. IV.: Constituents of the Root of *Sophora angustifolia* SIEB. et ZUCC. (1). *Yakugaku Zasshi* 90, 463–468. doi:10.1248/yakushi1947.90.4\_463
- Kumar, S., Kumar, R., Dwivedi, A., and Pandey, A. K. (2014). *In Vitro* Antioxidant, Antibacterial, and Cytotoxic Activity and *In Vivo* Effect of Syngonium Podophyllum and *Eichhornia crassipes* Leaf Extracts on Isoniazid Induced Oxidative Stress and Hepatic Markers. *Biomed. Res. Int.* 2014, 459452. doi:10.1155/2014/459452
- Kumar, S., and Pandey, A. K. (2013). Chemistry and Biological Activities of Flavonoids: An Overview. *ScientificWorldJournal* 2013, 162750. doi:10.1155/2013/162750
- Kumar, S. (2014). *Secondary Metabolite and Functional Food Components: Role in Health and Disease*. New York: Nova Science Publisher Inc.
- Kushwaha, P. P., Singh, A. K., Prajapati, K. S., Shuaib, M., Fayed, S., Bringmann, G., et al. (2020a). Induction of Apoptosis in Breast Cancer Cells by Naphthylisoquinoline Alkaloids. *Toxicol. Appl. Pharmacol.* 409, 115297. doi:10.1016/j.taap.2020.115297
- Kushwaha, P. P., Singh, A. K., Shuaib, M., Prajapati, K. S., Vardhan, P. S., Gupta, S., et al. (2020b). 3-O-(E)-p-Coumaroyl Betulinic Acid Possess Anticancer Activity and Inhibit Notch Signaling Pathway in Breast Cancer Cells and Mammosphere. *Chem. Biol. Interact.* 328, 109200. doi:10.1016/j.cbi.2020.109200
- Kushwaha, P. P., Vardhan, P. S., Kapewangolo, P., Shuaib, M., Prajapati, S. K., Singh, A. K., et al. (2019a). Bulbine Frutescens Phytochemical Inhibits Notch Signaling Pathway and Induces Apoptosis in Triple Negative and Luminal Breast Cancer Cells. *Life Sci.* 234, 116783. doi:10.1016/j.lfs.2019.116783
- Kushwaha, P. P., Kumar, R., Neog, P. R., Behara, M. R., Singh, P., Kumar, A., et al. (2021). Characterization of Phytochemicals and Validation of Antioxidant and Anticancer Activity in Some Indian Polyherbal Ayurvedic Products. *Vegetos* 34, 286–299. doi:10.1007/s42535-021-00205-1
- Kushwaha, P. P., Prajapati, K. S., Pothabathula, S. V., Singh, A. K., Shuaib, M., Joshi, K., et al. (2019b). *Prenylated Flavonoids as a Promising Drug Discovery Candidate: A Pharmacological Update*. Netherlands: Elsevier.
- Lee, S., Chae, M. R., Lee, B. C., Kim, Y. C., Choi, J. S., Lee, S. W., et al. (2016). Urinary Bladder-Relaxant Effect of Kurarinone Depending on Potentiation of Large-Conductance Ca<sup>2+</sup>-Activated K<sup>+</sup> Channels. *Mol. Pharmacol.* 90, 140–150. doi:10.1124/mol.115.102939
- Lee, S., Choi, J. S., and Park, C. S. (2018). Direct Activation of the Large-Conductance Calcium-Activated Potassium Channel by Flavonoids Isolated from *Sophora flavescens*. *Biol. Pharm. Bull.* 41, 1295–1298. doi:10.1248/bpb.b18-00250
- Lee, S. W., Lee, H. S., Nam, J. Y., Kwon, O. E., Baek, J. A., Chang, J. S., et al. (2005). Kurarinone Isolated from *Sophora flavescens* Ait Inhibited MCP-1-Induced Chemotaxis. *J. Ethnopharmacol.* 97, 515–519. doi:10.1016/j.jep.2004.12.006
- Li, W., Liang, H., Yin, T., Wang, B., and Zhao, Y. Y. (2008). Main Flavonoids from *Sophora Flavescens*. *Yao Xue Xue Bao* 43, 833–837.
- Liang, S., Li, Y., Zhang, X., Guo, Y., and Pan, S. (2021). Molecular Evidence of Compound Kushen Injection Against Lung Cancer: A Network Pharmacology-Based Investigation from Western Medicine to Traditional Medicine. *Anticancer Agents Med. Chem.* 21, 2012–2022. doi:10.2174/1871520621666210126090632
- Ma, H. Y., Zhou, W. S., Chu, F. J., Wang, D., Liang, S. W., and Li, S. (2013). HPLC Fingerprint of Flavonoids in *Sophora flavescens* and Determination of Five Components. *Zhongguo Zhong Yao Za Zhi* 38, 2690–2695.
- Mashraqi, M. M., Chaturvedi, N., Alam, Q., Alshamrani, S., Bahnass, M. M., Ahmad, K., et al. (2021). Biocomputational Prediction Approach Targeting FimH by Natural SGLT2 Inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 Inhibitor Drugs. *Molecules* 26, 582. doi:10.3390/molecules26030582
- Min, J. S., Kim, D. E., Jin, Y. H., and Kwon, S. (2020). Kurarinone Inhibits HCoV-OC43 Infection by Impairing the Virus-Induced Autophagic Flux in MRC-5 Human Lung Cells. *J. Clin. Med.* 9, 2230. doi:10.3390/jcm9072230
- Mishra, A., Sharma, A. K., Kumar, S., Saxena, A. K., and Pandey, A. K. (2013). Bauhinia Variegata Leaf Extracts Exhibit Considerable Antibacterial, Antioxidant, and Anticancer Activities. *Biomed. Res. Int.* 2013, 915436. doi:10.1155/2013/915436
- Nishikawa, S., Inoue, Y., Hori, Y., Miyajima, C., Morishita, D., Ohoka, N., et al. (2020). Anti-Inflammatory Activity of Kurarinone Involves Induction of HO-1 via the KEAP1/Nrf2 Pathway. *Antioxidants* 9, 1–15. doi:10.3390/antiox9090842
- Nishikawa, S., Itoh, Y., Tokugawa, M., Inoue, Y., Nakashima, K. I., Hori, Y., et al. (2019). Kurarinone from *Sophora Flavescens* Roots Triggers ATF4 Activation and Cytostatic Effects through PERK Phosphorylation. *Molecules* 24, 1–13. doi:10.3390/molecules24173110
- Pan, Z. S., Yu, Q. H., Yan, H., and Zhang, Y. (2005). Clinical Study on Treatment of Chronic Hepatitis B by Kurarinone Combined with Interferon Alpha-1b. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 25, 700–703.
- Park, S. J., Nam, K. W., Lee, H. J., Cho, E. Y., Koo, U., and Mar, W. (2009). Neuroprotective Effects of an Alkaloid-free Ethyl Acetate Extract from the Root of *Sophora flavescens* Ait. Against Focal Cerebral Ischemia in Rats. *Phytomedicine* 16, 1042–1051. doi:10.1016/j.phymed.2009.03.017
- Piao, X. L., Piao, X. S., Kim, S. W., Park, J. H., Kim, H. Y., and Cai, S. Q. (2006). Identification and Characterization of Antioxidants from *Sophora flavescens*. *Biol. Pharm. Bull.* 29, 1911–1915. doi:10.1248/bpb.29.1911
- Qin, Y., Zhu, Y., Xue, X., Zhou, G., Li, H., and Wang, J. (2020). An *In Vitro* Study for Evaluating Permeability and Metabolism of Kurarinone. *Evid. Based Complement. Alternat. Med.* 2020, 5267684. doi:10.1155/2020/5267684
- Ryu, Y. B., Westwood, I. M., Kang, N. S., Kim, H. Y., Kim, J. H., Moon, Y. H., et al. (2008). Kurarinol, Tyrosinase Inhibitor Isolated from the Root of *Sophora flavescens*. *Phytomedicine* 15, 612–618. doi:10.1016/j.phymed.2007.09.022
- Sahlan, M., Devina, A., Pratami, D. K., Situmorang, H., Farida, S., Munim, A., et al. (2019). Anti-inflammatory Activity of *Tetragronula* Species from Indonesia. *Saudi. J. Biol. Sci.* 26, 1531–1538. doi:10.1016/j.sjbs.2018.12.008
- Sasaki, T., Li, W., Higai, K., Quang, T. H., Kim, Y. H., and Koike, K. (2014). Protein Tyrosine Phosphatase 1B Inhibitory Activity of Lavandulyl Flavonoids from Roots of *Sophora flavescens*. *Planta Med.* 80, 557–560. doi:10.1055/s-0034-1368400
- Sato, S., Takeo, J., Aoyama, C., and Kawahara, H. (2007). Na<sup>+</sup>-Glucose Cotransporter (SGLT) Inhibitory Flavonoids from the Roots of *Sophora flavescens*. *Bioorg. Med. Chem.* 15, 3445–3449. doi:10.1016/j.bmc.2007.03.011
- Seo, O. W., Kim, J. H., Lee, K. S., Lee, K. S., Kim, J. H., Won, M. H., et al. (2012). Kurarinone Promotes TRAIL-Induced Apoptosis by Inhibiting NF- $\kappa$ B-dependent cFLIP Expression in HeLa Cells. *Exp. Mol. Med.* 44, 653–664. doi:10.3858/em.2012.44.11.074
- Shi, Y. Q., Xin, X. L., Yuan, Q. P., Wang, C. Y., Zhang, B. J., Hou, J., et al. (2012b). Microbial Biotransformation of Kurarinone by *Cunninghamella Echinulata* AS 3.3400. *J. Asian Nat. Prod. Res.* 14, 1002–1007. doi:10.1080/10286020.2012.681049
- Shi, Y. Q., Xin, X. L., Zhang, H. C., Zhang, B. J., Wang, C. Y., Hou, J., et al. (2012a). Microbial Transformation of Norkurarinone by *Cunninghamella blakesleana* AS 3.970. *J. Asian Nat. Prod. Res.* 14, 906–912. doi:10.1080/10286020.2012.702759
- Sohn, H. Y., Son, K. H., Kwon, C. S., Kwon, G. S., and Kang, S. S. (2004). Antimicrobial and Cytotoxic Activity of 18 Prenylated Flavonoids Isolated from Medicinal Plants: *Morus alba* L., *Morus mongolica schneider*, *Broussonetia papyrifera* (L.) Vent, *Sophora flavescens* Ait and *Echinosophora koreensis* Nakai. *Phytomedicine* 11, 666–672. doi:10.1016/j.phymed.2003.09.005
- Son, J. K., Park, J. S., Kim, J. A., Kim, Y., Chung, S. R., and Lee, S. H. (2003). Prenylated Flavonoids from the Roots of *Sophora flavescens* with Tyrosinase Inhibitory Activity. *Planta Med.* 69, 559–561. doi:10.1055/s-2003-40643
- Song, S. S., Sun, C. P., Zhou, J. J., and Chu, L. (2019). Flavonoids as Human Carboxylesterase 2 Inhibitors: Inhibition Potentials and Molecular Docking Simulations. *Int. J. Biol. Macromol.* 131, 201–208. doi:10.1016/j.ijbiomac.2019.03.060



- Sun, M. Y., Zuo, J., Duan, J. F., Han, J., Fan, S. M., Zhang, W., et al. (2008). Zhong Xi Yi Jie He Xue Bao. *J. Chin. Integrat. Med.* 6, 51–59. doi:10.3736/jcim20080111
- Suzuki, R., Hasuike, Y., Hirabayashi, M., Fukuda, T., Okada, Y., and Shirataki, Y. (2013). Identification of a Xanthine Oxidase-Inhibitory Component from *Sophora flavescens* Using NMR-Based Metabolomics. *Nat. Prod. Commun.* 8, 1409–1412. doi:10.1177/1934578x1300801017
- Tan, R. X., Wolfender, J. L., Zhang, L. X., Ma, W. G., Fuzzati, N., Marston, A., et al. (1996). Acyl Secoiridoids and Antifungal Constituents from *Gentiana Macrophylla*. *Phytochemistry* 42, 1305–1313. doi:10.1016/0031-9422(96)00149-5
- Tang, K. T., Lin, C. C., Lin, S. C., Wang, J. H., and Tsai, S. W. (2021). Kurarinone Attenuates Collagen-Induced Arthritis in Mice by Inhibiting Th1/Th17 Cell Responses and Oxidative Stress. *Int. J. Mol. Sci.* 22, 1–16. doi:10.3390/ijms22084002
- Wang, X., Zhen, L., Zhang, G., Wong, M. S., Qin, L., and Yao, X. (2011). Osteogenic Effects of Flavonoid Aglycones from an Osteoprotective Fraction of *Drynaria Fortunei*-Aan *In Vitro* Efficacy Study. *Phytomedicine* 18, 868–872. doi:10.1016/j.phymed.2011.01.022
- Xie, L., Gong, W., Chen, J., Xie, H. W., Wang, M., Yin, X. P., et al. (2018). The Flavonoid Kurarinone Inhibits Clinical Progression of EAE Through Inhibiting Th1 and Th17 Cell Differentiation and Proliferation. *Int. Immunopharmacol.* 62, 227–236. doi:10.1016/j.intimp.2018.06.022
- Yamahara, J., Kobayashi, G., Iwamoto, M., Chisaka, T., Fujimura, H., Takaishi, Y., et al. (1990). Vasodilatory Active Principles of *Sophora flavescens* Root. *J. Ethnopharmacol.* 29, 79–85. doi:10.1016/0378-8741(90)90100-8
- Yang, J., Chen, H., Wang, Q., Deng, S., Huang, M., Ma, X., et al. (2018). Inhibitory Effect of Kurarinone on Growth of Human Non-Small Cell Lung Cancer: An Experimental Study Both *In Vitro* and *In Vivo* Studies. *Front. Pharmacol.* 9, 252. doi:10.3389/fphar.2018.00252
- Yang, X., Baburin, I., Plitzko, I., Hering, S., and Hamburger, M. (2011). HPLC-based Activity Profiling for GABAA Receptor Modulators from the Traditional Chinese Herbal Drug Kushen (*Sophora flavescens* Root). *Mol. Divers.* 15, 361–372. doi:10.1007/s11030-010-9297-7
- Yang, Z., Zhang, W., Li, X., Shan, B., Liu, J., and Deng, W. (2016). Determination of Sophoraflavanone G and Kurarinone in Rat Plasma by UHPLC-MS/MS and its Application to a Pharmacokinetic Study. *J. Sep. Sci.* 39, 4344–4353. doi:10.1002/jssc.201600681
- Yu, Q., Cheng, N., and Ni, X. (2013). Identifying 2 Prenylflavanones as Potential Hepatotoxic Compounds in the Ethanol Extract of *Sophora flavescens*. *J. Food Sci.* 78, T1830–T1834. doi:10.1111/1750-3841.12275
- Zhang, C., Ma, Y., Gao, H. M., Liu, X. Q., Chen, L. M., Zhang, Q. W., et al. (2013). Non-alkaloid Components from *Sophora flavescens*. *Zhongguo Zhong Yao Za Zhi* 38, 3520–3524.
- Zhang, H. Q., Zhu, Z. H., Qian, D. W., Weng, Z. B., Guo, S., Duan, J. A., et al. (2016b). Analysis and Evaluation of Alkaloids and Flavonoids in Flower of *Sophora flavescens* from Shanxi Province. *Zhongguo Zhong Yao Za Zhi* 41, 4621–4627. doi:10.4268/cjcm20162422
- Zhang, L., Xu, L., Xiao, S. S., Liao, Q. F., Li, Q., Liang, J., et al. (2007). Characterization of Flavonoids in the Extract of *Sophora flavescens* Ait. By High-Performance Liquid Chromatography Coupled with Diode-Array Detector and Electrospray Ionization Mass Spectrometry. *J. Pharm. Biomed. Anal.* 44, 1019–1028. doi:10.1016/j.jpba.2007.04.019
- Zhang, Q., Yu, J., Wang, Y., and Su, W. (2016a). Selective Extraction of Flavonoids from *Sophora flavescens* Ait. By Mechanochemistry. *Molecules* 21, 1–14. doi:10.3390/molecules21080989
- Zhang, W. M., Li, R. F., Qiu, J. F., Zhang, Z. Y., Wang, H. B., Bian, L., et al. (2015). Determination of Kurarinone in Rat Plasma by UPLC-MS/MS. *J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.* 986–987, 31–34. doi:10.1016/j.jchromb.2015.02.005
- Zhang, X., Jiang, P., Chen, P., and Cheng, N. (2016). Metabolism of Kurarinone by Human Liver Microsomes and its Effect on Cytotoxicity. *Pharm. Biol.* 54, 619–627. doi:10.3109/13880209.2015.1070876
- Zhou, J., Zhang, L., Li, Q., Jin, W., Chen, W., Han, J., et al. (2018). Simultaneous Optimization for Ultrasound-Assisted Extraction and Antioxidant Activity of Flavonoids from *Sophora flavescens* Using Response Surface Methodology. *Molecules* 24, 1–15. doi:10.3390/molecules24010112
- Zhou, W., Cao, A., Wang, L., and Wu, D. (2015). Kurarinone Synergizes TRAIL-Induced Apoptosis in Gastric Cancer Cells. *Cell Biochem. Biophys.* 72, 241–249. doi:10.1007/s12013-014-0444-0

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Kumar, Prajapati, Shuaib, Kushwaha, Tuli and Singh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

## GLOSSARY

<b><math>\alpha</math>SMA</b>	smooth muscle actin	<b>MDA</b>	melanoma differentiation associated protein
<b>AST</b>	aspartate aminotransferase	<b>MIC</b>	minimum inhibitory concentration
<b>eIF2<math>\alpha</math></b>	eukaryotic translation initiation factor 2 $\alpha$	<b>MMP3/2/9</b>	matrix metalloproteinase
<b>EGFR</b>	epidermal growth factor receptor	<b>NADPH</b>	nicotinamide adenine dinucleotide phosphate
<b>ERK1/2</b>	extracellular signal regulated kinase 1/2	<b>NF-<math>\kappa</math>B</b>	necrosis factor- $\kappa$ B
<b>Grp78</b>	glucose-regulated protein	<b>NO</b>	nitric oxide
<b>GSH-Px</b>	plasma glutathione peroxidase	<b>Nrf2</b>	nuclear factor erythroid 2-related factor 2
<b>Her-2</b>	human epidermal growth factor receptor-2	<b>OATP1B3</b>	organic anion transporting polypeptide 1B3
<b>HEK293</b>	human embryonic kidney 293	<b>PARP</b>	poly (ADP-ribose) polymerase
<b>H<sub>2</sub>O<sub>2</sub></b>	hydrogen peroxide	<b>PERK-eIF2<math>\alpha</math></b>	protein kinase R (PRK) like endoplasmic reticulum
<b>IL-6/8/17A</b>	interleukin-6/8/17A	<b>PGK</b>	phosphoglycerate kinase
<b>iNOS</b>	inducible nitric oxide synthase	<b>p90RSK</b>	serine/threonine-protein kinase
<b>JAK/STAT</b>	Janus kinase/signal transducer and activator of transcription	<b>ROS</b>	reactive oxygen species
<b>JNK</b>	c-Jun N-terminal kinase	<b>SOD</b>	superoxide dismutase
<b>KDR</b>	kinase insert domain receptor	<b>S6RP</b>	S6 ribosomal protein
<b>KEAP</b>	Kelch-like-ECH-associated-protein	<b>TGF-<math>\beta</math>1</b>	Tumor growth factor $\beta$ 1
<b>LPS</b>	lipopolysaccharide	<b>Th1</b>	type 1T helper
<b>Mcl-1</b>	myeloid leukemia and chlamydia	<b>Th17</b>	type 17T helper
		<b>TNF-<math>\alpha</math></b>	tumor necrosis factor- $\alpha$
		<b>TRB3</b>	tribbles homolog